Sequenom Inc. and SensiGen LLC Expand Global Alliance
Published: Jul 31, 2008
SAN DIEGO & ANN ARBOR, Mich.--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ: SQNM), a leading provider of molecular diagnostic applications and genetic analysis products and services, and SensiGen LLC, a privately held biotechnology company focused on developing proprietary gene-based, molecular diagnostic tests, today announced expansion of their global alliance to develop and market advanced diagnostic tests and systems to commercial laboratories worldwide. Under the expanded agreement, in addition to commercializing SensiGen’s advanced test for human papillomavirus (HPV) exclusively on Sequenom’s MassARRAY® platform, SensiGen will also be the exclusive provider of MassARRAY platform-based assays for SensiGen’s newly developed Chronic Kidney Disease (CKD) and Lupus tests. Sequenom will exclusively supply platform technology and reagents used for commercializing SensiGen’s proprietary tests. The expanded agreement also provides Sequenom with the future right to a minority equity interest in SensiGen. Financial terms of the alliance were not disclosed.